Asian Cardio Diabetes Forum
Addressing Cardiovascular Outcomes in T2DM: Exploring Novel StrategiesAgenda - Mar. 30, 2019 - Hanoi, Vietnam
As a clinician with an interest in diabetes and cardiovascular disease, you are cordially invited to participate in the Asian Cardio Diabetes Forum
This Asian Cardio Diabetes Forum is designed to provide participants with new information and perspectives on effective strategies to help patients with diabetes and/or increased cardiovascular risk to reach their treatment goals. This will be a dynamic and interactive meeting with state-of-the-art lectures, clinical debates, and practical workshops where participants will discuss challenging clinical cases with international and regional experts. Participants will be part of an educational initiative that will provide support to clinicians in their daily clinical management of cardiovascular risk and diabetes. The program provides an optimal balance between updates in forefront science and clinical dialogue.
Date & Location
- March 30-31, 2019 - Saturday 14:00 - 18:30 hrs, Sunday - 09:00 - 12:15 hrs
- Meliá Hanoi - 44B Ly Thuong Kiet Street, Hanoi, Vietnam
The educational objectives of this Asian Cardio Diabetes Forum are:
- To explore mechanisms and common pathways underlying the development of cardiovascular disease in patients with diabetes
- To discuss novel insights into the outcomes of recent trials with anti-diabetic therapy, in particular with SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To discuss current and future strategies for practical management of cardiovascular risk, diabetes, heart failure and kidney disease
Session 1 – Diabetes & Cardiovascular Disease: What are the challenges?
- The burden of CVD & T2DM in South East Asia: Call for action - Pham Manh Hung, MD, Hanoi, Vietnam
- Cardiovascular disease: The new risk management challenge in diabetes - John E Deanfield, MD, London, United Kingdom
- Targeting HbA1c in diabetes management: What are the key lessons from glucose lowering trials - Nikolaus Marx, MD, Aachen, Germany
Session 2 – Game changing clinical trials in T2DM & CVD: Novel insights & implications
- Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials - Mark Cooper, MD, Melbourne, Australia
- SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits? - Nikolaus Marx, MD, Aachen, Germany
- Innovations in cardiovascular risk management: How best to tackle the risk? - John E Deanfield, MD, London, United Kingdom
Session 3 – New Frontiers in CVD, Diabetes & CKD
- Heart Failure: The next frontier for SGLT2 inhibitors? - Nikolaus Marx, MD, Aachen, Germany
- The Kidney: Opportunities for protection and prevention - Mark Cooper, MD, Melbourne, Australia
- Targeting risk in patients with CVD, Diabetes or CKD: new guidelines and risk management approaches - John E Deanfield, MD, London, United Kingdom
Session 4 – Practical workshop on risk management in CVD and Diabetes
- Interactive Case discussions - All faculty
Session 5 – Defining Key Take home messages
An application for CME accreditation will be submitted to EBAC, the European Board for Accreditation in Cardiology
Supervision of the scientific program is provided by the PACE board of Directors. The program and logistics in Hanoi are managed by MEDCON International on behalf of PACE-CME.
For more information please contact MEDCON International at: Tel + 31 23 5317 357 or e-mail, firstname.lastname@example.org.
This educational program is funded by an unrestricted educational grant provided by Boehringer Ingelheim